A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Recruiting · NCT06810960 · Observational (researchers observe without assigning treatment) · Lead sponsor: Eisai Korea Inc.
View the official record on ClinicalTrials.gov →Interventions studied
No Intervention
What this trial is about
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
- The clinical decision to treat with LEQEMBI has already been made
- Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.
Exclusion criteria
- Currently participating in an interventional clinical study
Where it is running
1 location listed across 1 US state.
- Eisai Trial Site #1 - Nutley, New Jersey, United States